Short answer · Medically reviewed summary · Last updated: 2026-04-07
The primary goal in treating Ankylosing Spondylitis is to reduce pain, maintain spinal mobility, and prevent long-term structural damage through a combination of non-steroidal anti-inflammatory drugs (NSAIDs), biologic therapies, and consistent physical therapy. Because Ankylosing Spondylitis is a systemic inflammatory condition, treatment is highly personalized and requires a multidisciplinary approach to manage symptoms across the skeletal, muscular, and immune systems. What are the first-line medical treatments for Ankylosing Spondylitis? For most patients, the first line of defense against Ankylosing Spondylitis involves the consistent use of non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen, ibuprofen, or celecoxib (Celebrex).
24 people with Ankylosing Spondylitis have shared their first-person experience on this question at DiseaseMaps.
The primary goal in treating Ankylosing Spondylitis is to reduce pain, maintain spinal mobility, and prevent long-term structural damage through a combination of non-steroidal anti-inflammatory drugs (NSAIDs), biologic therapies, and consistent physical therapy. Because Ankylosing Spondylitis is a systemic inflammatory condition, treatment is highly personalized and requires a multidisciplinary approach to manage symptoms across the skeletal, muscular, and immune systems.
For most patients, the first line of defense against Ankylosing Spondylitis involves the consistent use of non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen, ibuprofen, or celecoxib (Celebrex). These medications are effective at reducing inflammation and stiffness, which are hallmark symptoms of the condition. If NSAIDs are insufficient or if the disease shows signs of aggressive progression, rheumatologists often prescribe biologic disease-modifying antirheumatic drugs (bDMARDs). These medications target specific proteins in the immune system, such as Tumor Necrosis Factor (TNF) inhibitors (e.g., adalimumab, etanercept, or infliximab) or Interleukin-17 (IL-17) inhibitors (e.g., secukinumab or ixekizumab). It is crucial to note that treatment plans must be individualized, as what works for one patient may differ significantly for another.
Medication is only one part of the puzzle; non-pharmacological interventions are essential to preserve function and quality of life for those living with Ankylosing Spondylitis. Physical therapy is considered a cornerstone treatment, focusing on posture, flexibility, and strengthening exercises to counteract spinal stiffness. Occupational therapy can also provide strategies for modifying daily tasks to protect joints, particularly if the hips or shoulders are involved. While some patients explore herbal supplements, current clinical evidence does not support them as a replacement for standard medical care. Always discuss any supplemental approaches with your physician to avoid interactions with prescribed treatments.
Because Ankylosing Spondylitis affects multiple systems—including the skeletal, digestive, and nervous systems—a multidisciplinary care team is vital. Effective management typically involves the following specialists:
Research into Ankylosing Spondylitis is rapidly evolving, with ongoing clinical trials investigating newer JAK inhibitors and therapies targeting different pathways of the immune system. With over 2,109 members in the DiseaseMaps community, we see firsthand how varied the patient journey is. Researchers are increasingly focused on personalized medicine, aiming to identify biomarkers that predict which patients will respond best to specific biologic therapies, thereby reducing the "trial and error" phase of treatment.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice; please consult with your healthcare provider for diagnosis and treatment.